New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
10:55 EDTNKTR, BDSI, CCIH, BNNY, USG, IDIX, ACHN, DYN, SLXP, VIPHigh option volume stocks:
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
12:32 EDTVIPVimpelCom, CK Hutchison nearing Italian asset merger, Bloomberg reports
VimpelCom and CK Hutchison are nearing combining their wireless units in Italy to create Italy's largest mobile-phone company by customers, Bloomberg reports, citing people familiar with the matter. The companies are finishing up the details of the deal, with an announcement expected potentially in the next week at the earliest, the report says. The owners are discussing a possible capital increase of $2.2B for the entity, the report adds. Reference Link
July 23, 2015
17:14 EDTCCIHGIC Private reports 5.15% passive stake in ChinaCache
Subscribe for More Information
11:17 EDTUSGUSG unit served grand jury subpoena over gypsum drywall
Subscribe for More Information
08:04 EDTUSGUSG says outlook for all businesses 'bright'
08:03 EDTUSGUSG reports Q2 adjusted EPS 53c, consensus 46c
Subscribe for More Information
July 22, 2015
15:26 EDTUSGNotable companies reporting before tomorrow's open
Subscribe for More Information
July 17, 2015
10:03 EDTUSGHigh option volume stocks
High option volume stocks: EWC DF WPX CLSN TE CMA SWI CE VRSN USG
July 16, 2015
15:42 EDTNKTRNektar partner Baxalta releases complete data from Phase II/III BAX 855 study
Nektar Therapeutics (NKTR) reported that partner Baxalta announced the publication of the complete data from the Phase II/III pivotal study and Phase I trial of BAX 855 in Blood, the journal of the American Society of Hematology. BAX 855 is Baxalta's investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, a leading treatment for hemophilia A with more than 11 years of real-world patient experience. Through a collaboration with Nektar, BAX 855 leverages proprietary pegylation technology designed to prolong the amount of factor VIII available for use in the body. As previously disclosed, BAX 855 met the study's primary endpoint for the prevention of bleeding episodes and the treatment with prophylaxis compared to on-demand treatment. Patients in the twice-weekly prophylaxis arm of the trial experienced a 95% reduction in median annualized bleed rate as compared with those in the on-demand arm. BAX 855 was also effective in treating all bleeding episodes, 95.9% of which were controlled with one or two infusions at a median dose of 29.0 IU/kg per infusion.
11:36 EDTBDSIBioDelivery Sciences management to meet with FBR Capital
Meetings to be held in Minneapolis on July 22 and in Dallas on July 23 hosted by FBR Capital.
06:54 EDTVIPVimpelCom offers Telecel stake to Zimbabwe government, Reuters reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use